The newly approved RSV vaccine could be rolled out by fall 2023, in time for the typical winter surge in RSV infections.
Disiplin ilmiah, gaya jurnalistik
Artikel-artikel mengenai Moderna
Menampilkan 1 - 20 dari 64 artikel
Preventive and therapeutic vaccines both train the immune system to fight disease, but they are used in different ways.
Canadian scientists have made significant contributions during the pandemic response, including vital roles in developing COVID-19 vaccines. But underfunding puts the future of science in Canada at risk.
The CDC’s endorsement of the reformulated COVID-19 booster shots represents a major step in the effort to get more Americans boosted.
The UK has become the first country to approve the shot, which targets omicron alongside the original strain of SARS-CoV-2.
It’s natural to have questions about the risks and benefits of COVID vaccines in young children. Here’s what you need to know ahead of Australia’s rollout.
Is it time for a new generation of COVID vaccines? Here’s where the research is at.
On the horizon: A new omicron-focused version of the Moderna vaccine that may offer longer protection and a stronger immune response.
Waiving patent rights on COVID-19 vaccines and drugs is still crucial to ensure access globally, but the waiver on the table at the June World Trade Organization meeting doesn’t do the job.
Boosters and vaccinating children mean we’re relying on two pharmaceutical companies to supply Australia’s COVID vaccines. That needs to change.
Moves by Moderna and BioNTech to make vaccines themselves in African countries signal that the companies aren’t considering licensing its technology to a third party for local manufacture.
New research sheds light on how Canadian researchers developed a key component of the mRNA COVID-19 vaccines but failed to share it with the world
Parents can now choose Moderna to vaccinate their children against COVID. So how effective is it, and how does it compare with Pfizer?
Fewer people reported needing to miss work after their booster, compared to their second dose.
The new omicron variant of coronavirus has a number of mutations that may require manufacturers to update vaccines. The unique attributes of mRNA vaccines make updating them fast and easy.
Moderna claims its scientists alone invented the mRNA sequence used to produce its COVID-19 vaccine. The US government, which helped fund the drug, disagrees.
Properly engaged and monitored, Nigeria’s private sector can do more in COVID vaccination exercise.
Protection from infection wanes over time. So boosters will offer extra protection and hopefully reduce the spread of the virus even further.
As boosters are authorized for all three COVID-19 shots available in the US, the ability to swap out vaccine types looks to be a boon to the immune system.
There are very few situations where someone can’t have a COVID vaccine for medical reasons.
Kontributor teratas
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Professor of Medicine, University of Virginia
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Professor of Microbiology, School of Medicine, University of Washington
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Professor Emeritus of Health Policy and Management, York University, Canada
-
Assistant Professor, School of Professional Communication, Toronto Metropolitan University
-
Paediatrician at the Royal Childrens Hospital and Associate Professor and Clinician Scientist, University of Melbourne and MCRI, Murdoch Children's Research Institute
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Law, Villanova School of Law
-
Professorial Fellow, University of Canberra
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Reader in Bioethics, University of Portsmouth
-
Associate Professor of Epidemiology, University of San Francisco
-
Professor of Epidemiology, Population Interventions Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne
